Showing results (31-40 of 192) with videos related to
Sort By:
Pageof 20
Journal of Thoracic Disease|June 16, 2023
Sequential therapy with crizotinib and a second-generation ALK inhibitor versus direct therapy of a second-generation ALK inhibitor in ALK-positive advanced lung cancer: a real-world studyJingwen Wei, Huan Zhou, Zhengbo SongJournal of Translational Medicine|June 26, 2016
Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinomaZhengbo Song, Xinmin Yu, Guoping Cheng, et al.Oncotargets and Therapy|January 27, 2016
Patients harboring EGFR mutation after primary resistance to crizotinib and response to EGFR-tyrosine kinase inhibitorWenxian Wang, Xiaowen Jiang, Zhengbo Song, et al.World Journal of Surgical Oncology|December 20, 2012
Analysis of the tumor length and other prognosis factors in pT1-2 node-negative esophageal squamous cell carcinoma in a Chinese populationZhengbo Song, Jiwen Wang, Baochai Lin, et al.Journal of Thoracic Disease|September 11, 2023
Effect of baseline cancer pain on the efficacy of immunotherapy in lung cancer patientsHuan Zhou, Jingwen Wei, Wei Sun, et al.Journal of Thoracic Disease|September 11, 2023
Efficacy and safety of immune checkpoint inhibitors in lung large-cell neuroendocrine carcinomaZheng Shi, Jingwen Wei, Manyi Xu, et al.Molecular and Clinical Oncology|February 19, 2021
Baseline anemia and anemia grade are independent prognostic factors for stage IV non-small cell lung cancerCheng Chen, Zhengbo Song, Wenxian Wang, et al.Journal of the Chinese Medical Association : JCMA|June 18, 2013
Therapeutic efficacy of gefitinib and erlotinib in patients with advanced lung adenosquamous carcinomaZhengbo Song, Baochai Lin, Lan Shao, et al.Oncotargets and Therapy|October 17, 2019
The efficacy and safety of anlotinib treatment for advanced lung cancerLan Shao, Wenxian Wang, Zhengbo Song, et al.Journal of Cancer Research and Clinical Oncology|November 17, 2023
Efficacy of rechallenge immunotherapy after immune monotherapy resistance in patients with advanced non-small cell lung cancerManyi Xu, Yue Hao, Zheng Shi, et al.Pageof 20